Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAP3K12 | Q12852 | 4/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626461 | 0.89 | PIK3CA (0.47) | PKMPIK3CAHASPIN | |
| SCHEMBL625703 | 0.83 | MAP3K12 (0.44) | PIK3CAF2RL3MAP3K12 | |
| SCHEMBL626243 | 0.81 | MAP3K12 (0.46) | PIK3CAF2RL3MAP3K12 | |
| SCHEMBL626123 | 0.80 | RET (0.43) | PIK3CAMAP3K12 | |
| SCHEMBL625459 | 0.74 | MAP3K12 (0.41) | PIK3CAF2RL3MAP3K12 | |
| SCHEMBL627020 | 0.74 | RET (0.40) | PIK3CAF2RL3MAP3K12 | |
| SCHEMBL626263 | 0.73 | TNF (0.42) | MAPTTNFPIK3CAMAP3K12 | |
| SCHEMBL624439 | 0.73 | MAP3K12 (0.41) | PIK3CAMAP3K12 | |
| SCHEMBL627432 | 0.71 | RET (0.40) | PIK3CAMAP3K12 | |
| SCHEMBL625702 | 0.71 | PIK3CA (0.50) | PIK3CAMAP3K12HASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012020215-A1 | AMINO- IMIDAZOLOTHIADIAZOLES FOR USE AS PROTEIN OR LIPID KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2012-02-16 | — | — | WO | disclosed |